Please login to the form below

Apeiron

This page shows the latest Apeiron news and features for those working in and with pharma, biotech and healthcare.

Apeiron Biologics also got the go-ahead for Dinutuximab beta as a treatment for high-risk neuroblastoma, an orphan indication.

Sanofi and Novartis snap up immuno-oncology candidates

BioNtech - signed last year alongside smaller deals with Selecta, Evotec and Apeiron Biologics.
Sanofi forges $1.5bn cancer partnership with BioNTech

Set to develop five cancer therapies
Sanofi and Evotec to work together on diabetes and cancer

injections. Meanwhile, the two companies have also agreed to work together with Apeiron Biologics on novel, small-molecule immuno-oncology therapies. ... Sanofi will support two years of research funding for Evotec and Apeiron and could potentially yield
Advancing acquisitions

Apeiron Biologics AG/GSK. APN01 - recombinant human angiotensin converting enzyme 2 (rhACE2) in ARDS.
GSK enters licensing deal for ARDS enzyme

Apeiron has granted GSK exclusive rights to its APN01 enzyme, in phase I development to treat Acute Respiratory Distress Syndrome. ... The deal will see GSK pay Apeiron an up-front payment of £11m cash and equity investment.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Pharma deals in August 2015

Immunology deals. In addition to this and in keeping with the industry fashion, Sanofi has ventured into immuno-oncology with Evotec / Apeiron Biologics. ... As a strategic collaboration it is fairly risk sparing and accesses Apeiron's immunological

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

BMS appoints new commercial leader, Davies joins Eisai and more

Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... major near-term milestones of clinical-stage assets and support the expansion and
Apeiron bolsters management board

Peter Llewellyn-Davies joins as its CFO and CBO. Viennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of ... He said: “Apeiron is currently amongst the most

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Senior Account Manager / Account Director - MedComms - London: Highly competitive salary &package

Senior / Principal Medical Writers wanted - MedComms - Various U...: Excellent Remuneration Packages

Senior Medical Writer – Medical Communications – North West – In...: Excellent Remuneration Package

Experienced / Senior Medical Writer - Excellent Progression Oppo...: Excellent Salary and Benefits on offer

Editorial Assistants - Medical Communications agency - Cheshire: Excellent Remuneration Package

Add my company

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

PANDAS/PANS Awareness: A parent’s story: To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Leading AstraZeneca’s return to growth in Europe: PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing: Social media - friend or foe?...